Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Fotiou D, Ziogas DC, Migkou M, Panagiotidis I, Eleutherakis-Papaiakovou E, Kanellias N, Psimenou E, Marinaki S, Bacharaki D, Mparmparoussi D, Matsouka C, Giannouli S, Terpos E, Kastritis E. Dimopoulos MA, et al. Blood Cancer J. 2017 Jun 16;7(6):e571. doi: 10.1038/bcj.2017.49. Blood Cancer J. 2017. PMID: 28622304 Free PMC article. Clinical Trial. No abstract available.
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E, Migkou M, Christoulas D, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Iakovaki M, Panagiotidis I, Ziogas DC, Fotiou D, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Blood Cancer J. 2016 May 27;6(5):e428. doi: 10.1038/bcj.2016.37. Blood Cancer J. 2016. PMID: 27232930 Free PMC article.
High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.
Terpos E, Christoulas D, Kastritis E, Bagratuni T, Gavriatopoulou M, Roussou M, Papatheodorou A, Eleutherakis-Papaiakovou E, Kanellias N, Liakou C, Panagiotidis I, Migkou M, Kokkoris P, Moulopoulos LA, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Blood Cancer J. 2016 Oct 7;6(10):e482. doi: 10.1038/bcj.2016.90. Blood Cancer J. 2016. PMID: 27716740 Free PMC article.
Hematological malignancies: myeloma.
Dimopoulos MA, Kastritis E, Anagnostopoulos A. Dimopoulos MA, et al. Ann Oncol. 2006 Sep;17 Suppl 10:x137-43. doi: 10.1093/annonc/mdl251. Ann Oncol. 2006. PMID: 17018714 Free article. Review. No abstract available.
The role of novel drugs in multiple myeloma.
Dimopoulos MA, Kastritis E. Dimopoulos MA, et al. Ann Oncol. 2008 Sep;19 Suppl 7:vii121-7. doi: 10.1093/annonc/mdn444. Ann Oncol. 2008. PMID: 18790953 Free article. Review. No abstract available.
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Leukemia. 2009 Jun;23(6):1152-7. doi: 10.1038/leu.2008.402. Epub 2009 Feb 19. Leukemia. 2009. PMID: 19225533
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gavriatopoulou M, Migkou M, Tsionos K, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Ann Oncol. 2010 Jul;21(7):1561-1562. doi: 10.1093/annonc/mdq259. Epub 2010 May 23. Ann Oncol. 2010. PMID: 20497962 Free article. No abstract available.
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E. Dimopoulos MA, et al. Leukemia. 2010 Oct;24(10):1769-78. doi: 10.1038/leu.2010.175. Epub 2010 Aug 26. Leukemia. 2010. PMID: 20739955
Multiple myeloma.
Dimopoulos MA, Terpos E. Dimopoulos MA, et al. Ann Oncol. 2010 Oct;21 Suppl 7:vii143-50. doi: 10.1093/annonc/mdq370. Ann Oncol. 2010. PMID: 20943607 Free article. Review.
1,275 results